Arginine

Arginine

SCHEMBL460591

N=C(N)NCCC[C@H](N)C(=O)O.NC(=O)C[C@H](N)C(=O)O.NCCCC[C@H](N)C(=O)O

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACE

The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSR P00390 1/20 0.56
OTC P00480 1/20 0.43
GNAI3 P08754 1/20 0.43
GNAO1 P09471 1/20 0.43
GNAI1 P63096 1/20 0.43
DDAH1 O94760 3/20 0.41
NOS2 P35228 4/20 0.39
NOS3 P29474 3/20 0.39
NOS1 P29475 3/20 0.39
ALOX15 P16050 1/20 0.38
BLM P54132 1/20 0.38
PMP22 Q01453 1/20 0.38
KMT2A Q03164 1/20 0.38
ARG2 P78540 4/20 0.37
ARG1 P05089 3/20 0.37
CYP1A2 P05177 2/20 0.37
TSHR P16473 2/20 0.37
CYP3A4 P08684 1/20 0.37
CPB2 Q96IY4 1/20 0.36
GLA P06280 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Arginine SCHEMBL27551474 0.95 GSR (0.50) GSROTCGNAI3GNAO1GNAI1
Arginine SCHEMBL8957537 0.93 GSR (0.65) GSROTCGNAI3GNAO1GNAI1
Arginine SCHEMBL11660904 0.93 GSR (0.65) GSROTCGNAI3GNAO1GNAI1
Arginine SCHEMBL5698936 0.93 OTC (0.49) GSROTCDDAH1NOS2NOS3
Arginine SCHEMBL263652 0.93 OTC (0.49) GSROTCDDAH1NOS2NOS3
Arginine SCHEMBL6946785 0.93 OTC (0.49) GSROTCDDAH1NOS2NOS3
Arginine SCHEMBL1898345 0.93 OTC (0.49) GSROTCDDAH1NOS2NOS3
Arginine SCHEMBL3516723 0.93 GSR (0.65) GSROTCGNAI3GNAO1GNAI1
Arginine SCHEMBL20946267 0.93 OTC (0.49) GSROTCDDAH1NOS2NOS3
Arginine SCHEMBL15022773 0.93 GSR (0.65) GSROTCGNAI3GNAO1GNAI1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120065131-A1 COMPOSITIONS AND METHODS FOR TOPICAL APPLICATION AND TRANSDERMAL DELIVERY OF AN OLIGOPEPTIDE REVANCE THERAPEUTICS, INC. (US) 2012-03-15 US disclosed
US-8022179-B2 Compositions and methods for topical application and transdermal delivery of an oligopeptide REVANCE THERAPEUTICS, INC. (US) 2011-09-20 US disclosed
EP-1856139-B1 COMPOSITIONS AND METHODS FOR TOPICAL APPLICATION AND TRANSDERMAL DELIVERY OF AN OLIGOPEPTIDE REVANCE THERAPEUTICS INC (US) 2011-04-27 EP disclosed
US-20090247464-A1 Compositions and Methods for Topical Application and Transdermal Delivery of an Oligopeptide REVANCE THERAPEUTICS, INC. (US) 2009-10-01 US disclosed
EP-1856139-A2 COMPOSITIONS AND METHODS FOR TOPICAL APPLICATION AND TRANSDERMAL DELIVERY OF AN OLIGOPEPTIDE Revance Therapeutics, Inc. (US) 2007-11-21 EP disclosed
US-20070037252-A1 Compositions and methods for topical application and transdermal delivery of an oligopeptide REVANCE THERAPEUTICS, INC. (US) 2007-02-15 US disclosed
WO-2006094193-A2 COMPOSITIONS AND METHODS FOR TOPICAL APPLICATION AND TRANSDERMAL DELIVERY OF AN OLIGOPEPTIDE REVANCE THERAPEUTICS, INC. (US) 2006-09-08 WO disclosed